CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, today announced that its UCLA research team has achieved a critical milestone by creating a process to add any antibody to lipid nanoparticles (LNP) using “click chemistry”, for targeting cancer cells
CancerVax, Inc., the developer of breakthrough cancer drugs that will use the body’s immune system to fight cancer, today announced that its UCLA research team has created a promising new drug candidate for treating recurrent Ewing sarcoma, a deadly children’s cancer
CancerVax, Inc., developer of a breakthrough Universal Cancer Treatment that will use the body’s immune system to fight cancer, today announced that its Reg A+ offering has been qualified by the SEC allowing the Company to formally launch a funding round of up to $5 million. Proceeds from the SEC qualified Reg A+ offering will be used by the Company to continue work on its breakthrough cancer treatments
CancerVax, Inc., developer of a breakthrough universal cancer treatment that uses the body’s immune system to fight cancer, today announced that in a recent Company podcast its CEO, Ryan Davies, and Tempus Labs Chief Medical Officer for Oncology Dr. Ezra Cohen, discussed his time at Tempus Labs, Moores Cancer Center and University of Chicago